| 2024 | 2023 | |||
|---|---|---|---|---|
| Gross margin | -14,0 k € | -476.7% | -2,4 k € | |
| EBITDA | -14,0 k € | -476.7% | -2,4 k € | |
| Operating profit | -14,0 k € | -476.7% | -2,4 k € | |
| Profit/loss | -14,0 k € | -472.1% | -2,5 k € | |
| Equity | -6,5 k € | -186.1% | 7,5 k € | |
| Total assets | 301,0 € | -96.0% | 7,5 k € | |
| Cash | 15,0 € | -99.8% | 7,2 k € | |
| Debts | 6,8 k € | — | ||
Private limited company · Liège · incorporated on 03/08/2023
Private limited company loss-making in the latest fiscal year. Cash position declining (-99.8%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Key indicators
EXTRACELL BIOTECHNOLOGIES is a Private limited company incorporated in 2023. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Liège.